COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) is expected to release its quarterly earnings data on Wednesday, July 16th after market close, per Finnhub. Analysts are expecting revenue of $2,594,880 and earnings of -$0.14 per share.
You can see Quiver Quantitative's $CLGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COLLPLANT BIOTECHNOLOGIESNEW Hedge Fund Activity
We have seen 5 institutional investors add shares of COLLPLANT BIOTECHNOLOGIESNEW stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WATERS PARKERSON & CO., LLC added 13,250 shares (+inf%) to their portfolio in Q1 2025, for an estimated $34,185
- AMH EQUITY LTD added 8,500 shares (+7.3%) to their portfolio in Q1 2025, for an estimated $21,930
- BROWN ADVISORY INC removed 8,265 shares (-6.9%) from their portfolio in Q1 2025, for an estimated $21,323
- WELLS FARGO & COMPANY/MN added 3,000 shares (+35.7%) to their portfolio in Q1 2025, for an estimated $7,740
- UBS GROUP AG added 1,866 shares (+8.4%) to their portfolio in Q1 2025, for an estimated $4,814
- ROYAL BANK OF CANADA added 500 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,290
- PINNACLE ASSOCIATES LTD removed 500 shares (-0.1%) from their portfolio in Q1 2025, for an estimated $1,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COLLPLANT BIOTECHNOLOGIESNEW Analyst Ratings
Wall Street analysts have issued reports on $CLGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 05/30/2025
To track analyst ratings and price targets for COLLPLANT BIOTECHNOLOGIESNEW, check out Quiver Quantitative's $CLGN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
